Medifast FY2025 EPS Forecast Decreased by Zacks Research

Key Points

• Zacks Research has revised Medifast's FY2025 earnings per share forecast down to $0.02, significantly lower than the previous estimate of $0.06.
• Despite the earnings downgrade, Wall Street Zen upgraded Medifast's stock rating from "hold" to "buy".
• Medifast reported a quarterly earnings figure of $0.04 per share, which exceeded analysts' expectations by $0.26.

Medifast Inc (NYSE:MED - Free Report) - Equities research analysts at Zacks Research cut their FY2025 earnings per share estimates for Medifast in a research note issued on Monday, August 25th. Zacks Research analyst Team now anticipates that the specialty retailer will post earnings per share of $0.02 for the year, down from their previous forecast of $0.06. The consensus estimate for Medifast's current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast's Q4 2026 earnings at $0.13 EPS, Q1 2027 earnings at $0.12 EPS and FY2027 earnings at $0.50 EPS.

Separately, Wall Street Zen upgraded shares of Medifast from a "hold" rating to a "buy" rating in a research note on Thursday, May 1st. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Medifast has an average rating of "Hold" and an average target price of $16.50.

Medifast Stock Up 2.0%

NYSE:MED opened at $14.26 on Thursday. The company's 50 day moving average is $13.94 and its 200-day moving average is $13.72. Medifast has a 12 month low of $11.57 and a 12 month high of $21.98. The firm has a market cap of $156.66 million, a price-to-earnings ratio of 44.55 and a beta of 0.80.

Medifast (NYSE:MED - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The specialty retailer reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.26. Medifast had a return on equity of 2.00% and a net margin of 0.76%.The business had revenue of $105.56 million for the quarter, compared to the consensus estimate of $96.10 million. Medifast has set its Q3 2025 guidance at -0.600-0.00 EPS.

Institutional Trading of Medifast

Hedge funds have recently modified their holdings of the company. PNC Financial Services Group Inc. raised its stake in shares of Medifast by 261.8% in the second quarter. PNC Financial Services Group Inc. now owns 2,001 shares of the specialty retailer's stock valued at $28,000 after purchasing an additional 1,448 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Medifast by 370.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,144 shares of the specialty retailer's stock valued at $30,000 after buying an additional 1,688 shares during the period. GAMMA Investing LLC raised its stake in shares of Medifast by 3,207.2% in the 1st quarter. GAMMA Investing LLC now owns 3,208 shares of the specialty retailer's stock valued at $43,000 after buying an additional 3,111 shares in the last quarter. Strs Ohio bought a new position in shares of Medifast during the 1st quarter worth about $78,000. Finally, CWM LLC lifted its holdings in shares of Medifast by 564.6% during the 2nd quarter. CWM LLC now owns 7,457 shares of the specialty retailer's stock worth $105,000 after acquiring an additional 6,335 shares during the period. Institutional investors own 95.51% of the company's stock.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.